Telix Pharmaceuticals Shares Crash as It Agrees to Merge With Germany's ITM in Deal Worth Up to $2.35 Billion

Telix Pharmaceuticals confirmed on Monday that it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE, a privately held German radioisotope producer, in a transaction valued at up to US$2.35 billion. Telix shares crashed on the announcement even though, according to Investors.com, analysts covering the stock had voiced bullish views on the tie-up.

Deal structure and consideration

The transaction consideration was calculated off Telix's 30-day trailing volume-weighted average price on the ASX of A$16.65 prior to signing, converted at an assumed AUD/USD exchange rate of 0.71, according to Telix's announcement distributed via PR Newswire. On top of the equity consideration, Telix will assume US$302 million of net debt at closing and account for US$96 million of management equity rollover and transaction expenses payable by the sellers, with both figures subject to closing adjustments, the release said. Consideration paid to ITM shareholders at closing is also subject to indemnity holdbacks and to escrow, or lockup, restrictions on the shares issued at closing of up to 15 months, which may be waived in limited part to let sellers cover tax and transaction-expense liabilities.

Up to $700 million tied to ITM-11 milestones

Beyond the upfront consideration, the deal includes contingent payments of up to US$700 million linked to regulatory approvals and sales milestones for ITM-11, payable in cash or Telix shares at Telix's election. The regulatory tranche breaks down as US$100 million upon FDA approval of ITM-11 in its expected first indication, G1-G2 GEP-NETs, no later than December 31, 2027; US$100 million upon FDA approval for a G2-G3 GEP-NETs indication no later than December 31, 2030; and US$50 million upon FDA approval for a Lung NETs indication no later than December 31, 2031. A further US$450 million is contingent on ITM-11 net global sales in fiscal 2030 exceeding US$150 million. The companies' forward-looking language also references a planned NDA resubmission for ITM-11, indicating the asset has additional regulatory steps ahead of any of these approvals.

Ownership split and dilution

On completion, existing Telix shareholders are expected to own approximately 76.3% of the combined company, with ITM shareholders holding approximately 23.7% of Telix shares on issue, according to the Telix release. By our calculation, that is a 52.6 percentage-point gap between the two groups (76.3 minus 23.7). Our interpretation of those disclosed figures is that incoming ITM holders would end up with a little under a quarter of the enlarged register. That is the pro forma ownership split as disclosed by the company, not a market-implied dilution figure, since the release does not specify the exact number of new shares to be issued or Telix's current share count.

Approvals and expected timing

Telix's board of directors has approved the transaction, and as of signing, holders of over 90% of ITM's shares had also approved it, with the remaining ITM shareholders expected to sign joinder agreements to the share purchase agreement before closing. Telix said the deal is expected to close by the end of fiscal 2026, subject to Telix shareholder approval as required under ASX Listing Rules, regulatory approvals, and other customary closing conditions. A notice of meeting is expected to be sent to Telix shareholders for an extraordinary general meeting in November 2026.

Strategic rationale

Telix CEO Christian Behrenbruch said the merger "positions Telix at the forefront of the consolidation that is occurring as the industry matures," describing ITM as "the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation," and noted the companies have worked closely together for years. ITM CEO Andrew Cavey said joining the two companies "creates a company with unmatched breadth and depth across the value chain," adding that the combined group would be positioned to capitalize on "rapidly growing global demand for radiopharmaceuticals." Telix cited a third-party forecast from MEDraysintell's 2025 nuclear medicine market report projecting the global market will reach US$41 billion by 2034, though this is an industry forecast rather than a company-specific projection.

Telix's existing commercial base is concentrated in diagnostics: Illuccix is commercially available in 22 countries, and Gozellix and Pixclara both carry FDA approval for prostate and glioma imaging respectively. By contrast, Telix's three pivotal-stage therapeutic candidates, TLX591-Tx, TLX101-Tx and TLX250-Tx, have not received marketing authorizations in any jurisdiction, underscoring that much of the combined group's therapeutic upside, including ITM-11, remains dependent on future regulatory outcomes rather than current sales. The companies said any projected EBITDA benefits from the deal are subject to realizing targeted synergies and commercial timing assumptions and exclude one-off implementation costs.

Advisers

Morgan Stanley Australia acted as exclusive financial adviser to Telix, with Sidley Austin and Herbert Smith Freehills Kramer serving as legal counsel. Centerview Partners advised ITM, with Latham & Watkins as legal counsel.

Bottom Line

Telix is proposing to absorb a private German isotope supplier in a deal that would leave incoming ITM holders with roughly a quarter of the enlarged share register and adds up to US$700 million of milestone payments tied to ITM-11, an asset the companies' forward-looking statements say still faces a planned NDA resubmission. The structure gives ITM sellers a path to Telix equity, has Telix assuming US$302 million of net debt, and sets contingent payments against FDA approval deadlines running out to 2031, while Telix shareholders are set to vote on the transaction at an extraordinary general meeting expected in November 2026. Our reading of the initial market reaction — a share-price decline despite the bullish analyst commentary reported by Investors.com — is that investors are weighing near-term dilution and execution risk against the longer-dated regulatory and commercial milestones embedded in the deal.